Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
Celldex will present three abstracts at the EAACI Annual Congress in Istanbul on June 14, 2026, highlighting its mast cell-targeting pipeline. Two flash talks will cover barzolvolimab, presenting long-term treatment results in chronic spontaneous urticaria and psychometric validation data in cold urticaria.
Key figures
- Drug Name
- barzolvolimab, CDX-622
- Phase Of Trial
- Phase 1 (CDX-622), Phase 3 (barzolvolimab)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.